Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neurocosmetics Market Size, Trends and Insights By Product Type (Body Care, Face...
-
The protein therapeutics market is anticipated to grow from USD 375.3 billion in 2024 to USD 740.07 billion by 2034, achieving a CAGR of 7.08%.
-
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...
-
New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight ...
-
Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from...
-
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025 --In preclinical studies, REX-8756 elicited complete, rapid and...
-
Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2025-2030" report has been added to ResearchAndMarkets.com's offering. ...
-
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic...
-
Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2 Approbation basée sur l’étude de phase 2 TN-10 qui a démontré un retard significatif dans l’apparition...
-
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D...